{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["UNIVERSITY OF NEBRASKA MEDICAL CENTER"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1194674"],"scientific_name":["Homo sapiens"],"long_description":["Mantle cell lymphoma (MCL) is a genetically and clinically heterogeneous B-cell malignancy. We studied two MCL cohorts with differing treatment patterns: one enriched for immunochemotherapy, the other for chemotherapy alone. TP53 alterations are consistently associated with poor prognosis, whereas ATM mutations correlate with improved outcomes following rituximab-based chemotherapy. Based on recurrent genetic events, six clusters are identified and refined into three prognostic groups: high-risk (TP53 mutations and deletions at 17p13.3, 13q14.2, and 19p13.3), intermediate-risk (ATM and epigenetic regulator mutations, or gains at 8q/17q/15q), and low-risk (lacking TP53 alterations, rare ATM mutations without 11q deletions, gains at 3q, deletions at 6q). Transcriptomic analysis reveals... (for more see dbGaP study page.)"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Functional Genomics and Tumor Microenvironment Analysis Reveal Prognostic Biological Subtypes in Mantle Cell Lymphoma","description":"Functional Genomics and Tumor Microenvironment Analysis Reveal Prognostic Biological Subtypes in Mantle Cell Lymphoma","dates":{"last_updated":"2025-09-24","first_public":"2025-04-29"},"accession":"PRJNA1194674","cross_references":{"taxon":["9606"]}}